Hydroxyurea, crystalline powder

Leverantör: MP Biomedicals

Synonyms: N-(Aminocarbonyl)hydroxylamine, Hydroxycarbamide

0210202325 0210202301 0210202305 0210202310
ICNA0210202325EA 4750 SEK
ICNA0210202325 ICNA0210202301 ICNA0210202305 ICNA0210202310
Hydroxyurea, crystalline powder
Hydroxyurea

Hydroxyurea is a inhibitor of DNA synthesis in vivo, and an antiviral and antineoplastic agent which is S-phase specific.


A ribonucleotide reductase inhibitor - inhibits by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. Induces fetal hemoglobin production in sickle cell anemia patients.


It induces apoptosis of in vitro myelogenous leukemia lymphocytes, and the phosphorylation of FADD and p53. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS.


It is Anti-neoplastic. It inactivates ribonucleoside reductase by forming a free radical nitroxide that binds a tyrosyl free radical in the active site of the enzyme. This blocks the synthesis of deoxynucleotides, which inhibits DNA synthesis and induces synchronisation or cell death in S-phase.


Freely soluble in water (50 mg/ml-clear colourless solution) or hot alcohol.

Formel: CH₄N₂O₂
MW: 76,05 g/mol
Kokpunkt: 296 °C (1013 hPa)
Smältpunkt: 136…146 °C
Storage Temperature: Omgivande
MDL Number: MFCD00007943
CAS nummer: 127-07-1
EINECS: 204-821-7
Merck Index: 13,04874

Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Läs mer About VWR